Richard Aplenc

Richard
  
Aplenc
, 
MD, PhD, MSCE
Email: 
raplenc@mail.med.upenn.edu
Address: 
CTRB Room 4018 3501 Civic Center Blvd
2674267252
Expertise

Dr. Aplenc's research involves molecular epidemiology, pediatric cancer Phase I clinical trials, treatment of pediatric AML, and the use of genetic polymorphism data to predict treatment response to therapeutic interventions, particularly in pediatric cancer therapy.

Appointments
Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine (2002 – 2008)
Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (2008 – 2011)
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia (2011– present)
Education
PhD, Epidemiology, University of Pennsylvania (2011)
MSCE, Clinical Epidemiology and Biostatistics, University of Pennsylvania (2002)
MD, University of Virginia (1994)
A.B., Classics, Princeton University (1988)
Selected Publications
Kang T. I., Hexem K., Localio R., Aplenc R., Feudtner C.. The use of palliative chemotherapy in pediatric oncology patients: A national survey of pediatric oncologists. Pediatr Blood Cancer. Vol 60(1) . 2013 Jan:88-94.
Puumala S. E., Ross J. A., Aplenc R., Spector L. G.. Epidemiology of childhood acute myeloid leukemia.. Pediatr Blood Cancer. 2013 Jan:[Epub ahead of print].
Kavcic M., Fisher B. T., Li Y., Seif A., Torp K., Walker D. M., Huang Y. S., Lee G. H., Tasian S. K., Vujkovic M., Bagatell R., Aplenc R.. Induction Mortality and Resource Utilization in Children Treated for Acute Myeloid Leukemia at Free-Standing Pediatric Hospitals in the United States. Cancer. 2013:Accepted for Publication.
Grupp S. A., Kalos M., Barrett D., Aplenc R., Porter D. L., Rheingold S. R., Teachey D. T., Levine B. L., June C. H.. Induction of Complete Remissions of ALL by Chimeric Antigen Receptor-expressing T Cells. N Engl J Med. 2013:Accepted for Publication.
Fisher B. T., Gerber J. S., Leckerman K. H., Seif A. E., Huang Y. S., Li Y., Harris T., Torp K., Rheam D., Shah A., Walker D., Aplenc R.. Variation in Hospital Antibiotic Prescribing Practices for Children with Acute Lymphoblastic Leukemia. Leuk Lymphoma. 2012 Nov:[Epub ahead of print].
Walker D. M., Fisher B. T., Seif A. E., Huang Y. S., Torp K., Li Y., Aplenc R.. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the pediatric health information systems database. Pediatr Blood Cancer. 2012 Sept:[Epub ahead of print].
Sung L. S., Aplenc R., Alonzo T. A., Gerbing R., Gamis A. S.. Predictors and short-term outcomes of hyperleukocytosis in children withacute myeloid leukemia: a report from the Children' s Oncology Group.. Haematologica. Vol 97(11) . 2012 Jul:1770-3.
Meyer N. J., Daye Z. J., Rushefski M., Aplenc R., Lanken P. N., Shashaty M. G., Christie J. D., Feng R.. SNP-set analysis replicates acute lung injury genetic risk factors.. BMC medical genetics. Vol 13(1) . 2012 Jun:52.
Lambert M. P., Reznikov A., Grubbs A., Nguyen Y., Xiao L., Aplenc R., Raouva L., Poncz M.. Platelet Factor 4 Platelet Levels Are Inversely Correlated with Steady-State Platelet Counts and with Platelet Transfusion Needs in Pediatric Leukemia Patients.. J Throm Haemost. Vol 10(7) . 2012 May:1442-6.
Aplenc R., Fisher B. T., Huang Y. S., Li Y., Alonzo T. A., Gerbing R. B., Hall M., Bertoch D., Keren R., Seif A. E., Sung L., Adamson P. C., Gamis A.. Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group.. Pharmacoepidemiol Drug Saf. Vol 21 Suppl 2. 2012 May:37-43.